Key result
Oral ACE2 and angiotensin 1-7 reduce pulmonary hypertension markers ~40% in rats.
Why the study?
Pulmonary arterial hypertension is a deadly and uncurable disease characterized by remodeling of the pulmonary vasculature and increased pulmonary artery pressure.
Does oral delivery of bioencapsulated ACE2 and ANG-(1-7) attenuate pulmonary hypertension in monocrotaline-induced PAH rats?
Does oral delivery of bioencapsulated ACE2 and ANG-(1-7) attenuate pulmonary hypertension in monocrotaline-induced PAH rats?
Answers are grounded in this paper and cite their sources.
Oral delivery of plant-bioencapsulated ACE2 and ANG-(1-7) successfully attenuated pulmonary hypertension in a rat model without toxicity, suggesting potential for a novel oral protein therapy.
Pulmonary arterial hypertension (PAH) is a deadly and uncurable disease characterized by remodeling of the pulmonary vasculature and increased pulmonary artery pressure. Angiotensin Converting Enzyme 2 (ACE2) and its product, angiotensin-(1-7) [ANG-(1-7)] were expressed in lettuce chloroplasts to facilitate affordable oral drug delivery. Lyophilized lettuce cells were stable up to 28 months at ambient temperature with proper folding, assembly of CTB-ACE2/ANG-(1-7) and functionality. When the antibiotic resistance gene was removed, Ang1-7 expression was stable in subsequent generations in marker-free transplastomic lines. Oral gavage of monocrotaline-induced PAH rats resulted in dose-dependent delivery of ANG-(1-7) and ACE2 in plasma/tissues and PAH development was attenuated with decreases in right ventricular (RV) hypertrophy, RV systolic pressure, total pulmonary resistance and pulmonary artery remodeling. Such attenuation correlated well with alterations in the transcription of Ang-(1-7) receptor MAS and angiotensin II receptor AGTRI as well as IL-1β and TGF-β1. Toxicology studies showed that both male and female rats tolerated ~10-fold ACE2/ANG-(1-7) higher than efficacy dose. Plant cell wall degrading enzymes enhanced plasma levels of orally delivered protein drug bioencapsulated within plant cells. Efficient attenuation of PAH with no toxicity augurs well for clinical advancement of the first oral protein therapy to prevent/treat underlying pathology for this disease.
No takes yet. Share an insight, caveat, or question.
Daniell et al. (2019) studied Pulmonary arterial hypertension. Bioencapsulated CTB-ACE2 and CTB-Ang-(1-7) vs. Sham / Untreated MCT group was evaluated on Right ventricular hypertrophy, right ventricular systolic pressure, total pulmonary resistance index, and pulmonary artery remodeling (30-50% decrease). Oral delivery of bioencapsulated CTB-ACE2 and CTB-Ang-(1-7) attenuated pulmonary hypertension development in rats, evidenced by 30-50% decreases in right ventricular hypertrophy, right ventricular systolic pressure, and pulmonary artery remodeling.
Synapse has enriched 10 related papers. Consider them for comparative context: